Circulating tumor DNA tumor fraction as a biomarker in refractory metastatic colorectal cancer: findings from the CAVE-2 GOIM trial. (PubMed, J Liq Biopsy) - Sep 26, 2026 - "The CAVE-2 GOIM trial investigated the role of rechallenge with cetuximab ± avelumab in patients with circulating tumor DNA (ctDNA) (assessed with the FoundationOne Liquid assay) RAS/BRAF wild type (WT) mCRC. This data suggests that a higher ctDNA shedding might better refine cancer aggressiveness and metastatic load than tumor burden. Taken together these results highlights the strong prognostic value of ctDNA TF and the potential role for treatment personalization."
Biomarker • Circulating tumor DNA • Journal • Colorectal Cancer • Oncology • Solid Tumor • BRAF
|
|
Alberto Zaniboni; Alessandra Pia D'Agata; Alessio Cogoni; Andrea Sartore-Bianchi; Antonio Avallone; Carmine Pinto; Carminia Maria Della Corte; Claudia Nisi; Claudio Lotesoriere; Davide Ciardiello; Elena Ongaro; Erika Martinelli; Federica Papaccio; Ferdinando De Vita; Filippo Pietrantonio; Fortunato Ciardiello; Giampaolo Tortora; Giulia Martini; Giuseppe Curigliano; Giuseppe Santabarbara; Gloria Pellizzari; Lisa Salvatore; Lorenzo Antonuzzo; Luca Boscolo Bielo; Marco Messina; Maria Giulia Zampino; Nicola Fazio; Nicola Normanno; Paola Andena; Roberto Bordonaro; Rossana Berardi; Salvatore Pisconti; Salvatore Siena; Silvia Marchesi; Stefania Napolitano; Teresa Troiani; Tiziana Pia Latiano
|